NattoPharma: 1st Quarter 2016 earnings release

Please find attached the 1stQuarter 2016 Earnings Release. 

Highlights for the quarter,

  • Record quarter revenue at NOK 12,5 million, 84% growth compared to Q1’15
  • Gross Margin at 50,4%, up from 28% same quarter last year
  • EBITDA of NOK -1,7 million, improved from negative NOK -3,7 million same quarter last year
  • Cash and Cash Equivalents at the end of the period is NOK 26,7 million, up from NOK 24,7 million at last quarter end (Q4’15)
  • Continued focus on the restructuring of the company to position it for expected growth, as well as focus on key performance indicators to deliver improved financial results

A presentation will be held via webcast by CEO Daniel H. Rosenbaum and CFO Kjetil Ramsøy at 10 am CET, Friday 20th May, followed by a Q&A session directly thereafter.

Please follow the below link to join the webcast;

http://webtv.hegnar.no/presentation.php?webcastId=33172211 

For more information, please contact:

Kjetil Ramsøy

CFO, NattoPharma

Mobil: +47 906 12 943

E-mail: kjetil.ramsoy@nattopharma.com

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

About NattoPharma and MenaQ7®

NattoPharma ASA, based in Norway, is the world's leader in vitamin K2 R&D. NattoPharma is the exclusive international supplier of MenaQ7® Vitamin K2 as MK-7, the best documented, commercially available Vitamin K2 as MK-7 with guaranteed actives and stability, clinical substantiation, and international patents granted and pending. The company has a multi-year research and development program to substantiate and discover the health benefits of vitamin K2 for applications in the marketplace for functional food and dietary supplements. With a global presence, the company established its North American subsidiary, NattoPharma USA, Inc., in Metuchen, NJ.

For more information, visit www.nattopharma.com or www.Menaq7.com

Tags:

About Us

NattoPharma, the world leader in Vitamin K2 Research and Development, has invested millions of dollars in in-vitro, in-vivo, and clinical studies to document the effects of MenaQ7® Vitamin K2 as MK-7. This commitment has created the only patented and clinically validated K2 on the market. After establishing the first commercial Vitamin K2 with its flagship brand, MenaQ7®, NattoPharma has consistently answered and met market needs through the development of new production technologies:• In 2012, the company introduced MenaQ7® Crystals, which represented an important breakthrough in the new generation of Vitamin K2 products, producing the purest natural MK-7 available.• In 2014, NattoPharma introduced the only all-trans nature-identical synthesized Vitamin K2, MenaQ7® PURE. Not only did the company succeed in changing the market with MenaQ7® PURE – offering a high-quality, competitively priced ingredient – but its efforts were rewarded with the NutrAward for Best Functional Ingredient at Natural Products West/engredea 2015. Vitamin K2 is essential for the body to utilize calcium to build healthy, strong bones and to inhibit calcium deposits in the arteries. Published clinical studies have demonstrated the high bioavailability and proof of efficacy for Nattopharma’s all-trans MK-7 products in healthy and diseased populations, for bone and cardiovascular health. NattoPharma continues to build its competitive advantage through focuson IPR and has patents both granted and pending related to relevant healthbenefits and market segments, creating extra value for its customers. And NattoPharma staff consists of professionals people with longstanding experience in medical and biochemical research as well as pharmaceutical and food supplement development. By understanding and controlling the chemistry, NattoPharma provides the market all-trans MK-7 products, while our sales and marketing team has extensive knowledge of international market demands with which it supports our partners.